TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05329103: A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Sponsor: Peel Therapeutics Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 65 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT05329103 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05329103 Rescue Dossier →